EUROPAISCHER VEREIN FUR KARDIOVASKULARE UND ENDOVASKULARE CHIRURGIE

Their core work

The European Society for Cardiovascular and Endovascular Surgery (ESCVS) is a pan-European professional association of practicing cardiovascular and vascular surgeons, headquartered in Zurich. In H2020 projects, they function as a clinical bridge: contributing surgical expertise, access to patient cohorts, and real-world procedural validation that purely academic or engineering partners cannot provide. Their two H2020 participations span both the diagnostic side of cardiovascular care (risk-stratifying carotid artery disease patients to decide who should undergo surgery) and the surgical innovation side (evaluating a laser-assisted system for minimally invasive coronary bypass). As a society rather than a single hospital, they carry authority to disseminate clinical findings and training protocols across the European surgical community.

What they specialise in

How they've shifted over time

In their first H2020 engagement (TAXINOMISIS, from 2018), the focus was squarely on the pre-surgical decision: how to use omics, pharmacogenomics, and computational modeling to stratify which carotid artery patients actually need intervention, placing them in the intersection of precision medicine and vascular surgery. By 2019, with SAFE-CAB, the emphasis shifted downstream to the operating theatre itself — evaluating a laser-assisted device for coronary bypass and developing a training platform for surgeons to adopt the new technique. The trajectory moves from "who should have surgery and why" toward "how to perform surgery better and spread that knowledge," suggesting growing engagement with the medical device and surgical innovation ecosystem.

Their trajectory points toward surgical device innovation and clinical trial partnerships, making them a useful validator and disseminator for medtech companies developing cardiovascular instruments who need credible European surgical society endorsement.

How they like to work

ESCVS has participated exclusively as a consortium partner — never as project coordinator — which is typical for professional societies that contribute clinical validation and community reach rather than driving the research agenda. Despite only two projects, they engaged with 21 unique partners across 10 countries, suggesting they join broad international consortia where their role is well-scoped. Working with them likely means accessing a validated clinical network and surgical community authority, in exchange for involving them in patient-facing or dissemination workpackages.

Across just two projects, ESCVS built connections with 21 unique partners in 10 countries, reflecting the wide European clinical networks that large health RIA and IA consortia typically assemble. No data indicates repeated partner relationships, suggesting they are brought in selectively for their specific clinical profile rather than through established consortia loyalty.

What sets them apart

Unlike a single hospital or research institute, ESCVS is a European-level professional society, meaning their participation carries implicit endorsement from a surgical community that spans many countries and clinical centres. For a medtech company or biotech startup needing clinical credibility and a path to surgeon adoption, a professional society partner is fundamentally different from a single-site clinical partner. Their combination of vascular and cardiac scope — covering both carotid disease and coronary bypass — is also relatively rare, positioning them across two of the highest-volume areas in cardiovascular surgery.

Highlights from their portfolio

• SAFE-CAB
  The largest funding award (EUR 190,375) and the most commercially relevant scope — evaluating a laser-assisted bypass device in a clinical trial with a surgical training platform — making it an example of deep medtech-clinical society collaboration.
• TAXINOMISIS
  A rare fusion of omics, pharmacogenomics, and computational modeling applied directly to surgical decision-making in carotid disease, demonstrating the society's willingness to engage with data-driven precision medicine approaches alongside traditional clinical expertise.